首页> 外文期刊>Diabetes >P-Selectin Glycoprotein Ligand-1 Deficiency Is Protective Against Obesity-Related Insulin Resistance
【24h】

P-Selectin Glycoprotein Ligand-1 Deficiency Is Protective Against Obesity-Related Insulin Resistance

机译:P-选择蛋白糖蛋白配体1缺乏症可预防肥胖相关的胰岛素抵抗

获取原文
获取原文并翻译 | 示例
           

摘要

Objective-an inflammatory process is involved in the mechanism of obesity-related insulin resistance. Recent studies indicate that monocyte chemoattractant protein-1 (mcp-1) is a major chemokine that promotes monocyte infiltration into adipose tissues; however, the adhesion pathway in adipose tissues remains unclear. We aimed to clarify the adhesion molecules that mediate monocyte infiltration into adipose tissue. Research design and methods-we used a dna microarray to compare the gene expression profiles in epididy-mal white adipose tissues (ewat) between db/db mice and c57/bl6 mice each fed a high-fat diet (hfd) or a low-fat diet (lfd). We investigated the change of insulin resistance and inflammation in ewat in p-selectin glycoprotein ligand-1 (psgl-1) homozygous knockout (psgl-1~(-1-)) mice compared with wild-type (wt) mice fed hfd. Results-dna microarray analysis revealed that psgl-1, a major ligand for selectins, is upregulated in ewat from both db/db mice and wt mice fed hfd. Quantitative real-time rt-pcr and immunohistochemistry showed that psgl-1 is expressed on both endothelial cells and macrophages in ewat of obese mice. Psgl-1~(-1-) mice fed hfd showed a remarkable reduction of macrophage accumulation and expression of proinflammatory genes, including mcp-1 in ewat. Moreover, adipocyte hypertrophy, insulin resistance, lipid metabolism, and hepatic fatty change were improved in psgl-1~(-1-) mice compared with wt mice fed hfd. Conclusions-these results indicate that psgl-1 is a crucial adhesion molecule for the recruitment of monocytes into adipose tissues in obese mice, making it a candidate for a novel therapeutic target for the prevention of obesity-related insulin resistance. Diabetes 60:189-199, 2011
机译:目的-炎症过程与肥胖相关的胰岛素抵抗的机制有关。最近的研究表明,单核细胞趋化蛋白1(mcp-1)是一种主要的趋化因子,可促进单核细胞浸润到脂肪组织中。然而,脂肪组织中的粘附途径仍不清楚。我们旨在阐明介导单核细胞浸润到脂肪组织中的粘附分子。研究设计和方法-我们使用dna芯片比较db / db小鼠和高脂饮食(hfd)或低脂饮食的c57 / bl6小鼠的附睾-白色脂肪组织(ewat)中的基因表达谱脂肪饮食(lfd)。我们调查了p-选择素糖蛋白配体1(psgl-1)纯合敲除(psgl-1〜(-1-))小鼠与喂hfd的野生型(wt)小鼠相比,胰岛素抵抗和ewat中炎症的变化。结果-dna芯片分析表明,psgl-1是选择素的主要配体,在db / db小鼠和喂hfd的wt小鼠的ewat中均被上调。实时定量rt-pcr和免疫组化显示,psgl-1在肥胖小鼠的子宫内膜内皮细胞和巨噬细胞中均有表达。用hfd喂养的Psgl-1〜(-1-)小鼠显示出巨噬细胞积聚和促炎基因(包括mcp-1)在ewat中的表达明显减少。此外,与喂食hfd的wt小鼠相比,psgl-1〜(-1-)小鼠的脂肪细胞肥大,胰岛素抵抗,脂质代谢和肝脂肪改变得到改善。结论-这些结果表明psgl-1是肥胖小鼠中单核细胞募集到脂肪组织中的关键粘附分子,使其成为预防肥胖相关胰岛素抵抗的新型治疗靶标的候选者。糖尿病60:189-199,2011年

著录项

  • 来源
    《Diabetes》 |2011年第1期|p.189-199|共11页
  • 作者单位

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,Department of Diabetic Nephropathy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,Department of Diabetic Nephropathy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号